Literature DB >> 15454424

Effects of the geometry of the immunological synapse on the delivery of effector molecules.

Daniel Coombs1, Byron Goldstein.   

Abstract

Recent experiments focusing on the function of the immunological synapse formed between a T cell and an antigen-presenting cell raise many questions about its purpose. We examine the proposal that the close apposition of the cell membranes in the central region of the synapse acts to focus T-cell secretions on the target cell, thus reducing the effect on nearby cells. We show that the efficiency of targeted T-cell responses to closely apposed cells is only weakly dependent on the distance between the cells. We also calculate effective (diffusion-limited) rates of binding and unbinding for molecules secreted within the synapse. We apply our model to the stimulation of B cells by secreted interleukin-4 (IL-4), and find that very few molecules of IL-4 need be released to essentially saturate the IL-4 receptors on the B-cell surface. Copyright 2004 Biophysical Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454424      PMCID: PMC1304647          DOI: 10.1529/biophysj.104.045674

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  29 in total

Review 1.  Formation and function of the immunological synapse.

Authors:  P Anton van der Merwe
Journal:  Curr Opin Immunol       Date:  2002-06       Impact factor: 7.486

Review 2.  New views of the immunological synapse: variations in assembly and function.

Authors:  Jordan Jacobelli; Pietro G Andres; Judie Boisvert; Matthew F Krummel
Journal:  Curr Opin Immunol       Date:  2004-06       Impact factor: 7.486

3.  Polarized expression of cytokines in cell conjugates of helper T cells and splenic B cells.

Authors:  A Kupfer; T R Mosmann; H Kupfer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

4.  Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells.

Authors:  J W Lowenthal; B E Castle; J Christiansen; J Schreurs; D Rennick; N Arai; P Hoy; Y Takebe; M Howard
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

5.  Reorientation and fusion of cytotoxic T lymphocyte granules after interaction with target cells as determined by high resolution cinemicrography.

Authors:  J R Yannelli; J A Sullivan; G L Mandell; V H Engelhard
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

6.  Role of diffusion in ligand binding to macromolecules and cell-bound receptors.

Authors:  D Shoup; A Szabo
Journal:  Biophys J       Date:  1982-10       Impact factor: 4.033

7.  Serial triggering of many T-cell receptors by a few peptide-MHC complexes.

Authors:  S Valitutti; S Müller; M Cella; E Padovan; A Lanzavecchia
Journal:  Nature       Date:  1995-05-11       Impact factor: 49.962

8.  Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4.

Authors:  M Kondo; T Takeshita; N Ishii; M Nakamura; S Watanabe; K Arai; K Sugamura
Journal:  Science       Date:  1993-12-17       Impact factor: 47.728

9.  Internalization of human interleukin 4 and transient down-regulation of its receptor in the CD23-inducible Jijoye cells.

Authors:  J P Galizzi; C E Zuber; H Cabrillat; O Djossou; J Banchereau
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

10.  Small splenic B cells that bind to antigen-specific T helper (Th) cells and face the site of cytokine production in the Th cells selectively proliferate: immunofluorescence microscopic studies of Th-B antigen-presenting cell interactions.

Authors:  H Kupfer; C R Monks; A Kupfer
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Design Parameters for Granzyme-Mediated Cytotoxic Lymphocyte Target-Cell Killing and Specificity.

Authors:  Daniel J Woodsworth; Valentin Dunsing; Daniel Coombs
Journal:  Biophys J       Date:  2015-08-04       Impact factor: 4.033

3.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

4.  Physical biology of the cancer cell glycocalyx.

Authors:  Joe Chin-Hun Kuo; Jay G Gandhi; Roseanna N Zia; Matthew J Paszek
Journal:  Nat Phys       Date:  2018-07-04       Impact factor: 20.034

5.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 6.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

Review 7.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

8.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 9.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

10.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.